In this study, we analyzed multiple somatic mutations in 10 genes relevant in melanoma tumorigenesis and targeted therapies. Overall, 45% of the tumors showed mutations and, in particular, 33% had multiple mutations. Based on our results, we conclude that the assessment of mutation status of multiple genes, including CDKN2A, could provide a genetic profile that can be useful as a prognostic and therapeutic marker in melanocytic tumors. © 2014 S. Karger AG, Basel.
Mutational profiling in melanocytic tumors: multiple somatic mutations and clinical implications / Richetta, A.G., Silvestri, V., Simona, G., Rizzolo, P., D'Epiro, S., Veronica, G., Mattozzi, C., Navazio, A.S., Mario, F., Calvieri, S., Ottini, L.. - In: ONCOLOGY. - ISSN 0030-2414. - 86:2(2014), pp. 104-108. [10.1159/000356878]
Mutational profiling in melanocytic tumors: multiple somatic mutations and clinical implications.
RICHETTA, Antonio Giovanni;SILVESTRI, VALENTINA;RIZZOLO, PIERA;D'EPIRO, SARA;MATTOZZI, CARLO;NAVAZIO, ANNA SARA;CALVIERI, Stefano;OTTINI, LAURA
2014
Abstract
In this study, we analyzed multiple somatic mutations in 10 genes relevant in melanoma tumorigenesis and targeted therapies. Overall, 45% of the tumors showed mutations and, in particular, 33% had multiple mutations. Based on our results, we conclude that the assessment of mutation status of multiple genes, including CDKN2A, could provide a genetic profile that can be useful as a prognostic and therapeutic marker in melanocytic tumors. © 2014 S. Karger AG, Basel.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
